Table 1.
Surface antigen expression on the principal circulating murine and human monocyte subsetsa
| Murine Ly6C+ monocytes | Murine CX3CR1+ monocytes | Human CD14+ monocytes | Human CD16+ monocytes | References | |
|---|---|---|---|---|---|
| Monocyte markers | |||||
| CD11b | + | + | + | + | 16 |
| CD14 | ND | ND | ++ | +/− | 5 |
| CD16 (FcγRIII) | ND | ND | − | + | 5 |
| CD115 | + | + | ND | ND | 21 |
| F4/80 | + | + | ND | ND | 16 |
| Gr-1 (Ly6C/Ly6G) | ++ | +/− | ND | ND | 16 |
| Ly6C | ++ | +/− | ND | ND | 21 |
| Ly6G | − | − | ND | ND | 197 |
| Chemokine receptors | |||||
| CCR1 | ND | ND | + | − | 16, 10 |
| CCR2 | + | − | + | − | 17, 9, 10 |
| CCR4 | ND | ND | +/− | − | 16 |
| CCR5 | ND | ND | +/− | +/− | 9, 16, 10, 198 |
| CCR7 | ND | ND | +/− | − | 16 |
| CXCR1 | ND | ND | +/− | − | 16, 10 |
| CXCR2 | ND | ND | + | − | 16, 10 |
| CXCR4 | ND | ND | +/− | + | 16, 10 |
| CX3CR1 | +/− | ++ | +/− | ++ | 16, 10 |
| Other receptors and lineage markers | |||||
| 7/4 | + | − | ND | ND | 18 |
| CD4 | ND | ND | + | + | 199 |
| CD11a | + | ++ | ND | ND | 16, 10 |
| CD11c | − | + | + | + | 21, 16, 198, 199 |
| CD31 | + | + | + | + | 16 |
| CD32 (FcγRII) | ND | ND | + | ++ | 13 |
| CD33 | ND | ND | ++ | + | 13 |
| CD43 | − | + | ++ | + | 21 |
| CD49b | + | − | ND | ND | 16 |
| CD62L (L-selectin) | + | − | + | − | 17, 16, 10 |
| CD64 (FcγRI) | ND | ND | − | + | 12 |
| CD86 | ND | ND | + | ++ | 13 |
| MHC class II | Inducibleb | Inducibleb | + | ++ | 16 |
| NK1.1 | − | − | ND | ND | 16 |
| Scavenger receptor | ND | ND | +/− | + | 200 |
a
Surface expression levels have been arbitrarily designated as undetectable (−), marginal (+/−), positive (+), and high (++) based on flow cytometric analysis; ND, not determined.
b
MHC class II levels are marginal under homeostatic conditions but increase rapidly with infectious or inflammatory stimulation (16).